Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis

Company To Initially Target 70 Cancer Centers

Executive Summary

The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.

You may also be interested in...



Atavistik Bio Raises $60m For Metabolic Disease, Cancer Drug Discovery

The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.

FDA OKs Blueprint/Roche's Gavreto As Rival To Lilly's Retevmo

Regulators in the US have approved Gavreto for metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo.

Blueprint Medicine Gains US Approval For First Drug, Precision Medicine Ayvakit

The FDA has granted full approval to the drug based on Phase I efficacy data and safety studies, reflecting lack of existing treatment options

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel